Best of ESMO 2026 in JAPAN
解説演題一覧

【消化器がん1（肝胆膵）】　解説：宗 英 一郎 先生（慶應義塾大学病院）

演題番号	演　題	演　者
LBA8	Ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: a randomized, controlled, double-blinded, phase 3 trial (HARMONi-GI1)	Jian Zhou
3136RO	Randomised Phase II study of mFOLFIRINOX±SBRT in patients with high risk, borderline resectable or locally advanced pancreatic cancer: Results of the AGITG MASTERPLAN trial	Andrew Oar
LBA83	Seven-Valent mKRAS-specific Lymph Node Targeted Amphiphile Immunotherapy Versus Observation in Resected Pancreatic Ductal Adenocarcinoma (PDAC): the AMPLIFY-7P randomized Phase 2 study	Eileen M. O'Reilly

【消化器がん2（消化管）】　解説：白石 和寛 先生（名古屋医療センター）

演題番号	演　題	演　者
2875O	Pembrolizumab or placebo plus concurrent definitive chemoradiotherapy in esophageal and gastroesophageal junction (GEJ) cancer: the Phase 3 randomized KEYNOTE-975 study	Manish A Shah
LBA31	Biweekly versus conventional trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer: the pragmatic phase 3 PRABITAS trial	Hiroya Taniguchi
LBA7	CLARITY-Gastric 01 (CG-01): a Phase 3 study of sonesitatug vedotin (Sone-Ve) in second or later-line (2L+) advanced or metastatic Claudin 18.2 (CLDN18.2) positive gastroesophageal carcinoma (GEC)	Ruihua Xu

【婦人科がん】　解説：長谷川 幸清 先生（埼玉医科大学国際医療センター）

演題番号	演　題	演　者
LBA11	Sacituzumab Tirumotecan in Previously Treated Advanced or Recurrent Endometrial Cancer: Results from the Phase 3 TroFuse-005/ENGOT-en23/GOG-3095 Study	Domenica Lorusso
LBA12	KEYNOTE-C93/GOG-3064/ENGOT-en15: Phase 3, Randomized, Open-Label Study of First-Line (1L) Pembrolizumab (Pembro) vs Carboplatin (C) + Paclitaxel (P) in Mismatch Repair-Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (a/rEC)	Brian Slomovitz

【Others 1（頭頸部）】　解説：西條 憲 先生（東北大学）

演題番号	演　題	演　者
LBA43	Tam-Peli versus chemotherapy in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): a multicenter, randomized, open-label, phase 3 study (TAISHAN-301)	Shao Dong Hong
1539RO	Amivantamab + pembrolizumab + carboplatin in first-line recurrent/metastatic head & neck squamous cell cancer (1L R/M HNSCC): Results from the phase 1b/2 OrigAMI-4 study	Paul L Swiecicki

【肺がん1】　解説：酒谷 俊雄 先生（ NTT東日本関東病院）

演題番号	演　題	演　者
LBA5	Krascendo 1: efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC	Ferdinandos Skoulidis
LBA6	Osimertinib (osi) + savolitinib (savo) vs platinum–pemetrexed (plat–pem) in EGFRm MET-overexpressed (OE) and/or -amplified (AMP) advanced NSCLC post-osi: SAFFRON Phase (Ph) 3 primary results	Shun Lu
LBA66	Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatment for PD-L1 negative advanced non-squamous (nsq) NSCLC: randomized phase 3 OptiTROP-Lung06 study	Caicun Zhou

【肺がん2】　解説：古田 恵 先生（北海道大学）

演題番号	演　題	演　者
LBA3	Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial	Jacob Sands
3808O	Tarlatamab in Previously Treated SCLC: Extended Follow-up of Overall Survival from the Phase 3 DeLLphi-304 Trial	Charles M. Rudin

【Others 2（肉腫･他）】　解説：野村 基雄 先生（京都大学医学部附属病院）／土橋 賢司 先生（九州大学病院）

演題番号	演　題	演　者
LBA10	MOIO: Interim analyses of a Phase III Randomized Non Inferiority Trial Assessing Reduced Frequency Immune Checkpoint Inhibitors in Responding Patients with Advanced/Metastatic Cancer.	Gwenaëlle Gravis
LBA1	INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)	Georgina Long
LBA9	Risvutatug Rezetecan (Ris-Rez) versus Gemcitabine and Docetaxel (GD) in Heavily Pretreated Patients (pts) with Relapsed or Refractory (R/R) Osteosarcoma: Primary Results from the Phase 3 ARTEMIS-011 Study	Lu Xie

【乳がん1】　解説：酒井 瞳 先生（昭和医科大学）

演題番号	演　題	演　者
1RO	Overall survival from the Phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy	Kevin Kalinsky
LBA51	Results From KEYNOTE-B49: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (Pembro) vs Placebo (Pbo) Plus Chemotherapy (CT) in Participants (Pts) With HR+/HER2− Advanced Breast Cancer (ABC)	Hope Rugo
LBA96	First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients (pts) with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Exploratory analysis of pts with brain metastases in TROPION-Breast02	Rebecca Dent

【乳がん2】　解説：能澤 一樹 先生（名古屋市立大学）

演題番号	演　題	演　者
LBA23	Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer	Sara Hurvitz
LBA25	Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes	Dennis Slamon
542RO	Prognostic impact of postoperative ctDNA surveillance on relapse-free survival and molecular lead time in high-risk breast cancer: JCOG1204A1	Yukinori Ozaki

【泌尿器がん】　解説：竹村 弘司 先生（がん研究会有明病院）

演題番号	演　題	演　者
LBA2	Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: results from the Phase 3 VOLGA trial	Thomas Powles
3586O	First-line pembrolizumab + lenvatinib + belzutifan or MK-1308A + lenvatinib in advanced RCC: randomized open-label phase 3 LITESPARK-012 study	Toni K. Choueiri
3587O	Final analysis of the phase 3 LITESPARK-011 study: belzutifan (bel) plus lenvatinib (len) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy	Daniel Y C Heng